top of page

Aleksey Krylov

Aleksey Krylov is a serial entrepreneur and seasoned Chief Financial Officer (CFO) for high-growth businesses. With a venture investing and investment banking background, his track record includes over 70 fundraising, going-public, and M&A transactions. Aleksey is a natural leader with experience in managing teams and daily operations for high-growth organizations. 

Previously, Aleksey served as the CFO for CytoImmune Therapeutics for three years. He led the finance function within the organization during that transformative period, helped secure over $100 million in funding and managed the expansion of the workforce from five to over 60 employees. Furthermore, he played a pivotal role in building a cutting-edge commercial-scale cell and biologics manufacturing facility.

Previously, as CFO of DIH International, Aleksey led the NASDAQ IPO prep for the Swiss-Chinese medical equipment manufacturer, driving strategic initiatives to optimize growth and maximize shareholder value.

As CFO of SELLAS Life Sciences, he orchestrated a successful reverse merger of the company into a public company and secured SELLAS’ listing on NASDAQ. He also led a successful convertible PIPE fundraise.

Before his stints as a healthcare CFO, Aleksey spent 12 years as a family office investment professional. He oversaw principal minority and control investments exceeding $500 million across diverse industries, including life sciences, medical technologies, healthcare IT, and consumer products. He started his career as an equity capital markets banker with Cowen’s investment banking practice.

Aleksey holds an MBA from Columbia Business School and a Bachelor of Science in Business Administration from Babson College.

His ability to blend financial acumen, deal-making expertise, and operational leadership makes him an invaluable asset to life sciences and medical technology organizations, driving transformative growth and financial performance.

bottom of page